natgillin/translations-raw huggingface dataset:
In controlled and uncontrolled portions of the studies with a median follow-up of approximately 2 years, the incidence per 100 subject-years of upper respiratory tract infections was 36.0 events; 95% CI: 34.9, 37.2 for golimumab treated patients.
U kontroliranim i nekontroliranim dijelovima ispitivanja s medijanom praćenja približno 4 godine, za bolesnike liječene golimumabom je incidencija infekcija gornjih dišnih puteva na 100 bolesnik-godina iznosila 34,9 događaja; 95% CI: 33,8; 36,0.
In controlled and uncontrolled portions of the studies with a median follow-up of approximately 2 years, the incidence per 100 subject-years of upper respiratory tract infections was 36.0 events; 95% CI: 34.9, 37.2 for golimumab treated patients.
U kontroliranim i nekontroliranim dijelovima ispitivanja s medijanom praćenja približno 4 godine, za bolesnike liječene golimumabom je incidencija infekcija gornjih dišnih puteva na 100 bolesnik-godina iznosila 34,9 događaja; 95% CI: 33,8; 36.,0.
In controlled clinical studies in patients with AIDS-KS against a bleomycin/vincristine regimen, opportunistic infections were apparently more frequent during treatment with Caelyx.
U kontroliranim kliničkim ispitivanjima kod bolesnika s Kaposijevim sarkomom povezanim s AIDS- om u usporedbi s protokolom bleomicin/vinkristin, oportunističke infekcije bile su prividno češće za vrijeme liječenja Caelyxom.
In controlled clinical studies, 10 patients (0.5%) experienced a seizure out of 2051 patients treated with a daily dose of 160 mg enzalutamide, whereas one patient (< 0.1%) receiving placebo and one patient (0.3%) receiving bicalutamide, experienced a seizure.
U kontroliranim kliničkim ispitivanjima, 10 bolesnika (0,5%) od 2051 liječenih dnevnom dozom od 160 mg enzalutamida imalo je napadaje, dok je napadaje imao jedan bolesnik (< 0,1%) koji je primao placebo i jedan bolesnik (0,3%) koji je primao bikalutamid.
In controlled clinical studies, use of Aranesp and other ESAs have shown:
U kontroliranim kliničkim studijama, primjena Aranespa i drugih LSE je pokazala:
In controlled clinical studies, use of Epoetin alfa and other erythropoiesis-stimulating agents (ESAs) have shown:
U kontroliranim kliničkim ispitivanjima, primjena epoetina alfa i drugih faktora stimulacije eritropoeze pokazala je slijedeće:
In controlled clinical studies, use of Epoetin alfa and other ESAs have shown:
U kontroliranim kliničkim ispitivanjima, primjena epoetina alfa i drugih faktora stimulacije eritropoeze pokazala je slijedeće:
In controlled clinical studies, use of epoetin alfa and other ESAs have shown:
U kontroliranim kliničkim ispitivanjima, primjena epoetina alfa i drugih lijekova za stimulaciju eritropoeze pokazala je sljedeće:
In controlled clinical studies, use of epoetins alfa and other ESAs have been associated with decreased locoregional tumour control or decreased overall survival:
U kontroliranim kliničkim ispitivanjima, primjena epoetina alfa i drugih lijekova za stimulaciju eritropoeze bila je povezana sa smanjenom lokoregionalnom kontrolom tumora ili smanjenim ukupnim preživljenjem:
In controlled clinical studies, use of epoetins has shown:
U kontroliranim kliničkim ispitivanjima, uporaba epoetina pokazala je:
In controlled clinical studies, use of NeoRecormon and other erythropoiesis-stimulating agents (ESAs) have shown:
U kontroliranim kliničkim ispitivanjima pokazalo se da primjena lijeka NeoRecormon i drugih lijekova za stimulaciju eritropoeze (LSE) ima sljedeće učinke:
In controlled clinical trials (4 – 8 week duration) 52% of the pregabalin treated patients and 38% of the patients on placebo had at least a 50% improvement in HAM-A total score from baseline to endpoint.
U kontroliranim kliničkim ispitivanjima (u trajanju od 4-8 tjedana), u 52% bolesnika liječenih pregabalinom te 38% bolesnika koji su primali placebo je na kraju ispitivanja zabilježeno najmanje 50%-tno poboljšanje ukupnog rezultata na HAM-A ljestvici u odnosu na početne vrijednosti.
In controlled clinical trials conducted world–wide, indinavir was administered alone or in combination with other antiretroviral agents (zidovudine, didanosine, stavudine, and/or lamivudine) to approximately 2,000 patients, the majority of whom were adult Caucasian males (15 % females).
U kontroliranim kliničkim ispitivanjima provedenima diljem svijeta indinavir je primjenjivan samostalno ili u kombinaciji s drugim antiretrovirusnim lijekovima (zidovudin, didanozin, stavudin i/ili lamivudin) u približno 2000 bolesnika, od kojih su većina bili odrasli muškarci bijele rase (15% žena).
In controlled clinical trials, 23.8% of patients treated with Provenge required opioids (a single dose of pethidine) on the day of infusion for infusion reactions (see sections 4.4 and 4.8).
U kontroliranim kliničkim ispitivanjima, u 23,8% bolesnika liječenih lijekom Provenge zbog reakcije na infuziju bilo je potrebno primijeniti opioide (jedna doza petidina) na dan infuzije (vidjeti dio 4.4 i 4.8).
In controlled clinical trials, 97% of patients receiving tobramycin nebuliser solution achieved sputum concentrations 10-fold of the highest P. aeruginosa MIC cultured from the patient and 95% of patients receiving tobramycin nebuliser solution achieved 25-fold of the highest MIC.
U kontroliranim kliničkim ispitivanjima 97 % bolesnika koji su primali atomiziranu otopinu tobramicina postiglo je u sputumu 10 puta veće koncentracije od najviše MIK za P. aeruginosa izoliranog kod tih bolesnika i 95 % bolesnika koji su primali atomiziranu otopinu tobramicina postigli su 25 puta više vrijednosti od najviše vrijednosti MIK.
In controlled clinical trials, angioedema and hypersensitivity reactions occurred rarely during treatment with aliskiren with rates comparable to treatment with placebo or comparators.
U kontroliranim kliničkim ispitivanjima angioedem i reakcije preosjetljivost javljali su se rijetko tijekom liječenja aliskirenom uz stope koje se mogu usporediti s liječenjem placebom ili komparatora.
In controlled clinical trials, angioedema and hypersensitivity reactions occurred rarely during treatment with aliskiren with rates comparable to treatment with placebo or comparators.
U kontroliranim kliničkim ispitivanjima angioedem i reakcije preosjetljivosti javljali su se rijetko tijekom liječenja aliskirenom uz stope koje se mogu usporediti s liječenjem placebom ili komparatora.
In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommonly associated with the administration of Rasilez.
U kontroliranim kliničkim ispitivanjima su klinički značajne promjene standardnih laboratorijskih parametara bile manje često povezane s primjenom Rasileza.
In controlled clinical trials, infection occurred in 27.5% of subjects in the Provenge group and 27.7% of subjects in the control group.
U kontroliranim kliničkim ispitivanjima, infekcija se razvila u 27,5% ispitanika u skupini Provenge i 27,7% ispitanika u kontrolnoj skupini.
In controlled clinical trials, infusion associated reactions (IARs) were defined as any adverse event occurring during or within 24 hours of LEMTRADA infusion.
U kontroliranim kliničkim ispitivanjima, reakcije povezane s infuzijom opisuju se kao bilo koja nuspojava koja se pojavi tijekom infuzije lijeka LEMTRADA ili unutar 24 sata nakon nje.
In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed 4 microgram/mL even at maximum doses.
U kontroliranim kliničkim ispitivanjima najviše razine metformina u plazmi (Cmax) nisu prelazile 4 µg/ml, čak i pri najvišim dozama.
In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed 4 g/ml, even at maximum doses.
U kontroliranim kliničkim ispitivanjima, maksimalne razine metformina u plazmi (Cmax) nisu prelazile 4 g/ml, čak i kod najviših doza.
In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed µg/ml, even at maximum doses.
U kontroliranim kliničkim ispitivanjima najviše razine metformina u plazmi (Cmax) nisu prelazile 4 µg/ml, čak i pri najvišim dozama.
In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed µg/mL, even at maximum doses.
U kontroliranim kliničkim ispitivanjima najviše razine metformina u plazmi (Cmax) nisu čak ni pri najvišim dozama prelazile 5 µg/ml.
In controlled clinical trials, myocardial infarctions were observed in 0.8% of patients in the Provenge group compared with 0.3% of patients in the control group.
U kontroliranim kliničkim ispitivanjima, infarkt miokarda zabilježen je u 0,8% bolesnika u skupini Provenge u odnosu na 0,3% bolesnika u kontrolnoj skupini.
In controlled clinical trials, orally-administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily (bid) for 7 days or 50 mg once daily (od) for 3 days) had no clinically relevant adverse effects.
U kontroliranim kliničkim ispitivanjima apiksaban primijenjen peroralno zdravim ispitanicima u dozama od 50 mg na dan tijekom 3 do 7 dana (25 mg dvaput na dan tijekom 7 dana ili 50 mg jedanput na dan tijekom 3 dana) nije izazvao klinički značajne nuspojave.
In controlled clinical trials, periorbital and/or eyelid skin darkening in association with the use of travoprost has been reported in 0.2% of patients.
U kontroliranim kliničkim ispitivanjima, periorbitalno i/ili tamnjenje kože očnih vjeđa povezano s primjenom travoprosta prijavljeno je kod 0,2% bolesnika.
In controlled clinical trials, the dosing interval range was 1 – 15 weeks (see section 5.1).
U kontroliranim kliničkim ispitivanjima, interval doziranja iznosio je 1 - 15 tjedana (vidjeti dio 5.1).
In controlled clinical trials, the incidence of diarrhoea in Rasilez HCT-treated patients was 1.3% compared to 1.4% for aliskiren- or 1.9% for hydrochlorothiazide-treated patients.
U kontroliranim kliničkim ispitivanjima incidencija proljeva u bolesnika liječenih Rasilez HCT-om bila je 1,3% u usporedbi s 1,4% u bolesnika liječenih aliskirenom ili 1,9% u bolesnika liječenih hidroklorotiazidom.
In controlled clinical trials, the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin.
U kontroliranim kliničkim ispitivanjima incidencija zatajenja srca uz liječenje pioglitazonom bila je ista kao i u skupinama liječenim placebom, metforminom i sulfonilurejom, ali povećala se kad je korišten u kombiniranoj terapiji s inzulinom.
In controlled Phase 3 trials of Humira in patients with plaque Psoriasis with a control period duration ranging from 12 to 24 weeks, ALT elevations ≥ 3 x ULN occurred in 1.8% of Humira-treated patients and 1.8% of control-treated patients.
U kontroliranim ispitivanjima faze III u kojima se Humira primjenjivala u bolesnika s plak psorijazom, s kontrolnim razdobljem koje je trajalo u rasponu od 12 do 24 tjedna, povišenja razine ALT-a ≥ 3 x GGN zabilježena su u 1,8% bolesnika liječenih lijekom Humira i 1,8% bolesnika iz kontrolne skupine.
In controlled Phase 3 trials of Humira in patients with polyarticular juvenile idiopathic arthritis who were 4 to 17 years and enthesitis-related arthritis who were 6 to 17 years, ALT elevations ≥ 3 x ULN occurred in 6.1% of Humira-treated patients and 1.3% of control-treated patients.
U kontroliranim ispitivanjima faze III u kojima se Humira primjenjivala u bolesnika u dobi od 4 do 17 godina s poliartikularnim juvenilnim idiopatskim artritisom i u bolesnika u dobi od 6 do 17 godina s artritisom povezanim s entezitisom, povišenje ALT-a ≥ 3 x GGN zabilježeno je u 6,1% bolesnika liječenih lijekom Humira i 1,3% bolesnika iz kontrolne skupine.
In controlled Phase 3 trials of Humira in patients with rheumatoid arthritis and psoriatic arthritis with a control period duration ranging from 4 to 104 weeks, ALT elevations ≥ 3 x ULN occurred in 3.7% of Humira-treated patients and 1.6% of control-treated patients.
U kontroliranim ispitivanjima faze III u kojima se Humira primjenjivala u bolesnika s reumatoidnim artritisom i psorijatičnim artritisom, s kontrolnim razdobljem koje je trajalo u rasponu od 4 do 104 tjedna, povišenje razine ALT-a ≥3 x GGN (gornja granica normalnog raspona) zabilježeno je u 3,7% bolesnika liječenih lijekom Humira i 1,6% bolesnika iz kontrolne skupine.
In controlled studies in thrombocytopenic patients with HCV receiving interferon-based therapy (n=1,439), 38 out of 955 subjects (4%) treated with eltrombopag and 6 out of 484 subjects (1%) in the placebo group experienced thromboembolic events (TEEs).
U kontroliranim ispitivanjima bolesnika s trombocitopenijom i HCV-om koji su primali terapiju temeljenu na interferonu (n=1439), 38 od 955 ispitanika (4%) koji su primali eltrombopag, te 6 od 484 ispitanika (1%) u grupi s placebom imalo je tromboembolijske događaje (TED).
In controlled studies, 1 year of lamivudine therapy significantly suppressed HBV DNA replication (34-57 % of patients were below the assay detection limits (Abbott Genostics solution hybridization assay, LLOD < 1.6pg/ml)], normalised ALT level (40-72 % of patients), induced HBeAg seroconversion (HBeAg loss and HBeAb detection with HBV DNA loss [by conventional assay], 16- 18 % of patients), improved histology (38-52 % of patients had a  2 point decrease in the Knodell Histologic Activity Index [HAI]) and reduced progression of fibrosis (in 3-17 % of patients) and progression to cirrhosis.
U kontroliranim ispitivanjima jednogodišnja terapija lamivudinom značajno je smanjila replikaciju HBV DNK [34-57 % bolesnika bilo je ispod granice detekcije laboratorijskog testa (Abbott Genostics hibridizacijski test u otopini, LLOD < 1,6 pg/ml)}, normalizirala razinu ALT (40-72% bolesnika), potakla serokonverziju HBeAg (nestanak HBeAg i pojavu HBeAb protutijela uz gubitak HBV DNK [uobičajenim testovima], 16-18 % bolesnika), poboljšala histološke nalaze (u 38-52 % bolesnika Knodellov histološki indeks aktivnosti [HAI] smanjio se za ≥ 2 boda) i usporila progresiju fibroze (u 3-17% bolesnika) te progresiju u cirozu
In controlled studies, 1 year of lamivudine therapy significantly suppressed HBV DNA replication [34-57 % of patients were below the assay detection limits (Abbott Genostics solution hybridization assay, LLOD < 1.6pg/ml)}, normalised ALT level (40-72 % of patients), induced HBeAg seroconversion (HBeAg loss and HBeAb detection with HBV DNA loss [by conventional assay], 16- 18 % of patients), improved histology (38-52 % of patients had a  2 point decrease in the Knodell Histologic Activity Index [HAI]) and reduced progression of fibrosis (in 3-17 % of patients) and progression to cirrhosis.
U kontroliranim ispitivanjima jednogodišnja terapija lamivudinom značajno je smanjila replikaciju HBV DNK [34-57 % bolesnika bilo je ispod granice detekcije laboratorijskog testa (Abbott Genostics hibridizacijski test u otopini, LLOD < 1,6 pg/ml)}, normalizirala razinu ALT (40-72% bolesnika), potakla serokonverziju HbeAg (nestanak HbeAg i pojavu HbeAb protutijela uz gubitak HBV DNK [uobičajenim testovima], 16-18 % bolesnika), poboljšala histološke nalaze (u 38-52 % bolesnika Knodellov histološki indeks aktivnosti [HAI] smanjio se za ≥ 2 boda) i usporila progresiju fibroze (u 3-17% bolesnika) te progresiju u cirozu.
In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the first 12 weeks of treatment.
U kontroliranim ispitivanjima kod bolesnika s plak psorijazom otprilike 13,6% bolesnika liječenih Enbrelom razvilo je reakciju na mjestu primjene injekcije u usporedbi s 3,4% placebom liječenih bolesnika za vrijeme prvih 12 tjedana liječenja.
In controlled trials in susceptible animals, mortality was less than 1%.
U kontroliranim ispitivanjima u osjetljivih životinja mortalitet je bio niži od 1 %.
In COPD patients both systemic exposure and total urinary excretion of glycopyrronium at pharmacokinetic steady state increased about dose-proportionally over the (delivered) dose range of 44 to 176 µg.
U bolesnika s KOPB-om i sistemska izloženost i ukupno urinarno izlučivanje glikopironija u farmakokinetičkom stanju dinamičke ravnoteže povećali su se otprilike proporcionalno (isporučenoj) dozi u rasponu 44 do 176 µg.
In COPD, Aerivio Spiromax is used in adults who have had exacerbations (flare–ups) of the disease in the past and have significant symptoms despite regular treatment.
Aerivio Spiromax koristi se za liječenje odraslih osoba s KOPB-om s ponavljajućim egzacerbacijama u anamnezi (bolest se pogoršala) koji imaju značajne simptome unatoč redovitom liječenju.
In COPD, Airexar Spiromax is used in adults who have had exacerbations (flare–ups) of the disease in the past and have significant symptoms despite regular treatment.
Airexar Spiromax koristi se za liječenje odraslih osoba s KOPB-om s ponavljajućim egzacerbacijama u anamnezi (bolest se pogoršala) koji imaju značajne simptome unatoč redovitom liječenju.
In corifollitropin alfa, a peptide (a short chain of amino acids) is attached to the FSH to prolong its activity in the body.
Peptid (kratki lanac aminokiselina) veže se na FSH u korifolitropinu kako bi se produžilo djelovanje u tijelu.
In course 1 the incidence was 20 %, by courses 4 the incidence was 8 %.
Tijekom prvog ciklusa incidencija je bila 20%, a do četvrtog ciklusa incidencija je bila 8%.
In cranial MRI, if a strong clinical suspicion of a lesion persists despite a single dose contrast- enhanced MRI or when more accurate information on the number, size or extent of lesions might influence management or therapy of the patient, in subjects with normal renal function, a second bolus injection of 0.2 ml/kg (100 micromol/kg) may be administered within 30 minutes of the first injection as it may increase the diagnostic yield of the examination.
Kod prikaza kranijalnih struktura magnetskom rezonancijom, ukoliko je jako izražena klinička sumnja na postojanje lezije usprkos učinjenoj snimci MR praćenoj jednokratnom primjenom kontrastnog sredstva ili kada točniji podaci o broju, veličini ili proširenosti lezija mogu utjecati na zbrinjavanje ili liječenje bolesnika, može se kod osoba s normalnom funkcijom bubrega primijeniti i druga bolus injekcija od 0,2 ml/kg (100 mikromola/kg) unutar 30 minuta nakon prve injekcije kako bi se proširilo dijagnostičko područje ispitivanja.
In cranial MRI, if a strong clinical suspicion of a lesion persists despite a single dose contrast- enhanced MRI or when more accurate information on the number, size or extent of lesions might influence management or therapy of the patient, in subjects with normal renal function, a second bolus injection of 0.2ml/kg (100 micromol/kg) may be administered within 30 minutes of the first injection as it may increase the diagnostic yield of the examination.
Kod prikaza kranijalnih struktura magnetskom rezonancijom, ukoliko je jako izražena klinička sumnja na postojanje lezije usprkos učinjenoj snimci MR praćenoj jednokratnom primjenom kontrastnog sredstva ili kada točniji podaci o broju, veličini ili proširenosti lezija mogu utjecati na zbrinjavanje ili liječenje bolesnika, može se kod osoba s normalnom funkcijom bubrega primijeniti i druga bolus injekcija od 0,2 ml/kg (100 mikromola/kg) unutar 30 minuta nakon prve injekcije kako bi se proširilo dijagnostičko područje ispitivanja.
In Crohn’s disease clinical studies, less than 3% of patients treated with ustekinumab developed antibodies to ustekinumab.
U kliničkim ispitivanjima Crohnove bolesti u manje od 3% bolesnika liječenih ustekinumabom, razvila su se protutijela na ustekinumab.
In Crohn’s disease induction studies, no events of anaphylaxis or other serious infusion reactions were reported following the single intravenous dose.
U ispitivanjima uvodnog liječenja Crohnove bolesti, nisu bili prijavljeni događaji anafilaksije ili druge ozbiljne reakcije na infuziju nakon jedne intravenske doze.
In Crohn’s disease studies, concomitant use of immunosuppressants or corticosteroids did not appear to influence the safety or efficacy of STELARA.
U ispitivanjima Crohnove bolesti, nije zabilježeno da istodobna primjena imunosupresiva ili kortikosteroida utječe na sigurnost ili djelotvornost STELARE.
In Crohn’s disease studies, concomitant use of immunosuppressants or corticosteroids did not appear to influence the safety or efficacy of STELARA. (see section 4.4).
U ispitivanjima Crohnove bolesti, nije zabilježeno da istodobna primjena imunosupresiva ili kortikosteroida utječe na sigurnost ili djelotvornost STELARE. (vidjeti dio 4.4).
In Crohn’s disease, experience with re-administration if signs and symptoms of disease recur is limited and comparative data on the benefit/risk of the alternative strategies for continued treatment are lacking.
Iskustvo s ponovnom primjenom lijeka u slučaju ponovne pojave znakova i simptoma Crohnove bolesti ograničeno je i nema usporednih podataka o omjeru koristi i rizika alternativnih strategija za nastavak liječenja.
In Crohn’s disease, the CHMP considered that although the time required for improvement of symptoms may be longer and the size of the effect limited when compared with anti-TNF-alfa therapy, Entyvio still offers a benefit for patients because of its different mechanism of action and safety profile.
Kod Crohnove bolesti CHMP je smatrao da iako vrijeme potrebno za poboljšavanje simptoma može biti dulje, a učinak ograničen u usporedbi s anti-TNF-alfa terapijom, lijek Entyvio još uvijek nudi koristi za bolesnike zbog svog različitog mehanizma djelovanja i sigurnosnog profila.
In Crohn’s disease, the effects of Stelara in reducing symptoms in patients in whom other treatments had failed or who could not receive them were considered important, also given the unmet medical need of these patients.
U slučaju Crohnove bolesti učinci lijeka Stelara na ublažavanje simptoma u bolesnika kod kojih druge terapije nisu bile uspješne ili su bile kontraindicirane smatraju se važnima, uzimajući u obzir i nezadovoljenu medicinsku potrebu tih pacijenata.
In Crohn’s disease, treatment is started with Stelara concentrate.
Kod Crohnove bolesti terapija započinje koncentratom lijeka Stelara.
In CRVO and BRVO retinal ischaemia occurs and signals the release of VEGF which in turn destabilises the tight junctions, and promotes endothelial cell proliferation.
Kod CRVO i BRVO, nastupa ishemija mrežnice što signalizira oslobađanje VEGF-a, koji onda destabilizira čvrste spojeve i potiče proliferaciju endotelnih stanica.
In CRYSTAL, the proportion of subjects who experienced a complete resolution (defined as 100% resolution of at least one target tophus and no single tophus showing progression) of ≥1 target tophus was higher in the group treated with Zurampic 200 mg in combination with febuxostat compared with placebo in combination with febuxostat, although the difference was not statistically different (26% compared with 21%).
U ispitivanju CRYSTAL, udio ispitanika u kojih je postignuto potpuno povlačenje (definirano kao 100 %-tno povlačenje najmanje jednog ciljnog tofa i bez znakova progresije bilo kojeg tofa) jednog ili više ciljnih tofa bio je veći u skupini liječenoj lijekom Zurampic u dozi od 200 mg u kombinaciji s febuksostatom, u usporedbi s kombinacijom placeba i febuksostata, iako razlika nije bila statistički značajna (26% u usporedbi s 21%).
In CT-AMT-011- 02 faeces was also collected.
U ispitivanju CT-AMT-011-02 također je uzeta i stolica.
In CURE there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery.
U studiji CURE, u kojoj je klopidogrel primjenjivan istodobno uz ASK, nije bilo povećanja broja velikih krvarenja tijekom 7 dana nakon ugrađivanja srčane premosnice u bolesnika koji su lijekove prestali uzimati više od pet dana prije kirurškog zahvata.
In CURE, CLARITY, ACTIVE-A and one of the cohort studies (Trenk), no increased event rate was observed based on metaboliser status.
U studijama CURE, CLARITY, ACTIVE-A i jednoj od kohortnih studija (Trenk), nije uočena povećana učestalost slučajeva temeljena na metabolizatorskom statusu.